Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 3/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.39 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Embusartan SCHEMBL29409583 | 1.00 | BDKRB1 (0.41) | BDKRB1AGTR1AGTR2 | |
| Embusartan SCHEMBL5534640 | 0.95 | BDKRB1 (0.38) | BDKRB1AGTR1AGTR2 | |
| Embusartan SCHEMBL5537210 | 0.95 | BDKRB1 (0.38) | BDKRB1AGTR1AGTR2 | |
| SCHEMBL5814612 | 0.91 | AGTR1 (0.43) | AGTR1AGTR2 | |
| SCHEMBL8013981 | 0.91 | AGTR1 (0.39) | AGTR1AGTR2 | |
| SCHEMBL8009750 | 0.91 | — | — | |
| SCHEMBL8007180 | 0.90 | — | — | |
| SCHEMBL8433566 | 0.90 | — | — | |
| SCHEMBL9412776 | 0.90 | BDKRB1 (0.43) | BDKRB1AGTR1AGTR2 | |
| Embusartan SCHEMBL5537214 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1731 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082608-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE LTD. (SG) | 2025-03-13 | — | — | US | claimed |
| EP-4448096-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | Singapore Health Services Pte. Ltd. (SG) | 2024-10-23 | — | — | EP | claimed |
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | ADVERIO PHARMA GMBH (DE) | 2024-08-20 | — | — | US | claimed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | claimed |
| US-20240173302-A1 | TREATMENT OF INFLAMMATORY DISEASES | DIMERIX BIOSCIENCE PTY LTD. (AU) | 2024-05-30 | — | — | US | claimed |
| EP-4313024-A1 | TREATMENT OF INFLAMMATORY DISEASES | Dimerix Bioscience Pty Ltd (AU) | 2024-02-07 | — | — | EP | claimed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | claimed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | claimed |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | claimed |
| WO-2023111196-A1 | TREATMENT AND PREVENTION OF GLOMERULAR DISEASE | SINGAPORE HEALTH SERVICES PTE. LTD. (SG) | 2023-06-22 | — | — | WO | claimed |
| US-20050288272-A1 | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-12-29 | — | — | US | claimed |
| EP-1545540-A2 | COMBINATION THERAPY USING A DUAL PPAR ALPHA/GAMMA AGONIST AND AN ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST | Merck & Co., Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2005023182-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| WO-2004080488-A2 | COMBINED PREPARATIONS OF ACETYL SALICYLIC ACID WITH AN HMG-COA REDUCTASE INHIBITOR | BAYER HEALTHCARE AG (DE) | 2004-09-23 | — | — | WO | claimed |
| WO-2004017896-A2 | COMBINATION THERAPY USING A DUAL PPAR ALPHA/GAMMA AGONIST AND AN ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2004-03-04 | — | — | WO | claimed |
| EP-1258258-A1 | Implantable device comprising a stent and angiotensin II receptor antagonists | TERUMO KABUSHIKI KAISHA (JP) | 2002-11-20 | — | — | EP | claimed |
| US-20020168393-A1 | Implantable medical material and implantable medical device | TERUMO KABUSHIKI KAISHA (JP) | 2002-11-14 | — | — | US | claimed |
| WO-2000037075-A1 | COMBINATION OF AN AT1 ANGIOTENSIN II RECEPTOR ANTAGONIST AND AN IMMUNOSUPPRESSANT | SANOFI-SYNTHELABO (FR) | 2000-06-29 | — | — | WO | claimed |
| EP-0594019-B1 | 1-Biphenylmethyl-pyridone derivatives, their preparation and their use as angiotensin II antagonistes | BAYER AG (DE) | 2000-02-23 | — | — | EP | claimed |
| US-5863930-A | ATHEROSCLEROSIS TREATMENT FORMED BY REACTION OF PYRIDONES WITH BIPHENYLMETHYL HALOGEN | BAYER AKTIENGESELLSCHAFT (DE) | 1999-01-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | BDKRB1 41/4885AGTR1 5/4885AGTR2 11/4885 |
| US-12064429-B2 | Substituted 5-fluoro-1H-pyrazolopyridines and their use | PFKP, PON1, FABP3 | BDKRB1 623/4885AGTR1 190/4885AGTR2 210/4885 |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | MME, CTSC, REN | BDKRB1 1268/4885AGTR1 25/4885AGTR2 42/4885 |
| US-20050288272-A1 | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists | ECE1, EDNRA, MME | BDKRB1 132/4885AGTR1 6/4885AGTR2 7/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | BDKRB1 39/4885AGTR1 4/4885AGTR2 9/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | BDKRB1 41/4885AGTR1 5/4885AGTR2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.